Cartesian Therapeutics (RNAC) Competitors $11.23 +0.27 (+2.46%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$11.19 -0.04 (-0.36%) As of 08/22/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAC vs. PHVS, GPCR, TLRY, RCUS, LENZ, ZYME, SYRE, UPB, STOK, and VERVShould you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Pharvaris (PHVS), Structure Therapeutics (GPCR), Tilray Brands (TLRY), Arcus Biosciences (RCUS), LENZ Therapeutics (LENZ), Zymeworks (ZYME), Spyre Therapeutics (SYRE), Upstream Bio (UPB), Stoke Therapeutics (STOK), and Verve Therapeutics (VERV). These companies are all part of the "pharmaceutical products" industry. Cartesian Therapeutics vs. Its Competitors Pharvaris Structure Therapeutics Tilray Brands Arcus Biosciences LENZ Therapeutics Zymeworks Spyre Therapeutics Upstream Bio Stoke Therapeutics Verve Therapeutics Cartesian Therapeutics (NASDAQ:RNAC) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment. Do analysts rate RNAC or PHVS? Cartesian Therapeutics presently has a consensus target price of $40.00, suggesting a potential upside of 256.19%. Pharvaris has a consensus target price of $35.60, suggesting a potential upside of 53.98%. Given Cartesian Therapeutics' higher probable upside, research analysts plainly believe Cartesian Therapeutics is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Pharvaris 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more risk & volatility, RNAC or PHVS? Cartesian Therapeutics has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.81, indicating that its share price is 381% less volatile than the S&P 500. Does the media refer more to RNAC or PHVS? In the previous week, Pharvaris had 17 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 17 mentions for Pharvaris and 0 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.24 beat Pharvaris' score of 0.88 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cartesian Therapeutics Positive Pharvaris Positive Which has better earnings & valuation, RNAC or PHVS? Cartesian Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M7.50-$77.42M-$52.83-0.21PharvarisN/AN/A-$145.24M-$3.36-6.88 Do insiders and institutionals hold more shares of RNAC or PHVS? 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is RNAC or PHVS more profitable? Cartesian Therapeutics' return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets Cartesian TherapeuticsN/A N/A -6.36% Pharvaris N/A -69.09%-63.34% SummaryCartesian Therapeutics beats Pharvaris on 10 of the 14 factors compared between the two stocks. Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAC vs. The Competition Export to ExcelMetricCartesian TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$284.98M$3.11B$5.75B$9.62BDividend YieldN/A2.23%4.40%4.10%P/E Ratio-0.2121.1431.2526.05Price / Sales7.50345.39433.91193.97Price / CashN/A43.1937.7358.48Price / Book-112.308.129.536.61Net Income-$77.42M-$54.72M$3.26B$265.65M7 Day Performance-0.88%2.62%2.13%2.03%1 Month Performance-16.13%2.68%2.80%-0.31%1 Year Performance-18.33%10.93%30.68%19.06% Cartesian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNACCartesian Therapeutics2.4993 of 5 stars$11.23+2.5%$40.00+256.2%-16.0%$284.98M$38.91M-0.2164Positive NewsGap UpPHVSPharvaris2.6385 of 5 stars$22.16-0.6%$35.60+60.6%+27.0%$1.17BN/A-6.6030GPCRStructure Therapeutics2.6364 of 5 stars$19.96-0.8%$75.71+279.3%-49.9%$1.16BN/A-19.01136News CoverageTLRYTilray Brands2.4357 of 5 stars$1.14+10.7%$1.92+68.1%-38.5%$1.13B$210.48M-0.492,842RCUSArcus Biosciences2.4061 of 5 stars$10.45+0.6%$21.14+102.3%-40.6%$1.11B$258M-3.30500Positive NewsLENZLENZ Therapeutics1.2609 of 5 stars$38.77+2.4%$49.60+27.9%+80.0%$1.08BN/A-20.41110Gap UpZYMEZymeworks0.2048 of 5 stars$14.05-2.2%N/AN/A$1.08B$122.87M-14.48460SYRESpyre Therapeutics2.8888 of 5 stars$16.94-0.1%$53.40+215.2%-29.8%$1.02B$890K-4.9873Analyst UpgradeUPBUpstream Bio2.1053 of 5 stars$18.02-4.8%$56.50+213.5%N/A$1.02B$2.37M0.0038STOKStoke Therapeutics4.5637 of 5 stars$18.51+1.6%$25.57+38.1%+42.3%$997.86M$36.56M21.78100VERVVerve Therapeutics2.975 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110 Related Companies and Tools Related Companies PHVS Competitors GPCR Competitors TLRY Competitors RCUS Competitors LENZ Competitors ZYME Competitors SYRE Competitors UPB Competitors STOK Competitors VERV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAC) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access